N/A N=48 Gingival Bleeding and Von Willebrand Disease Typ 2 and 3
Gingival Bleeding · Von Willebrand Diseases
Primary: Bleeding on Probing (BOP) — 14.5; 12.3 percentage of sites
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=29 Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
Acquired Hemophilia A
Primary: Percentage of Serious Bleeding Episodes Responsive to OBI-1 — 100 percentage of serious bleeding episodes — p=<0.001
Phase 3 N=5 Study of TAK-672 in Participants With Acquired Hemophilia A
Acquired Hemophilia A
Primary: Percentage of Participants With Severe Bleeding Episodes Who Demonstrated Response to TAK-672 Therapy at 24 Hours After the Initiation of Treatment — 100 percentage of…
N/A N=56 Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment
Von Willebrand Diseases
Primary: Total Annualized Bleeding Rate (TABR) — 29.13 Bleeding events per year
N/A N=265 Type 3 Von Willebrand International Registries Inhibitor Prospective Study
Type 3 Von Willebrand's Disease
Primary: Centralized Factor VIII (FVIII) Procoagulant Activity (FVIII:C) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis — 2.42 IU/dL
Phase 3 N=25 Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery
Congenital Fibrinogen Deficiency
Primary: Overall Clinical Assessment of the Haemostatic Efficacy of Octafibrin in Treating the First Documented Bleeding Episode of Each Patient. — 19; 23; 5; 1 Participants
Phase 3 N=61 An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Factor XIII Deficiency
Primary: Adverse Events — 42; 2; 2 participants
Phase 3 N=20 Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial
Von Willebrand Diseases · Postpartum Hemorrhage
Primary: Volume of Quantitative Blood Loss at Delivery — 727.0; 539.7 mL
N/A N=72 Clinical Trial of Factor XIII (FXIII) Concentrate
Hemophilia · Factor XIII Deficiency
Primary: Response to Treatment of Bleeding Events Requiring Additional Factor XIII Infusions — 30; 1; 0; 3 Number of bleeds
N/A N=24 Coagulation Factor Changes Associated With Postpartum Hysterectomies
Obstetric Labor Complications · Hemorrhage · Complications; Cesarean Section
Primary: Fibrinogen Level at 2 Hours After Delivery — 186; 418 mg/dL — p=<0.05
Phase 3 N=38 Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen
Hemophilia A · Hemophilia B
Primary: Percentage of Bleeding Episode With "Treatment Success" — 96.19; 79.30 percent of bleeding episodes
Phase 2 N=122 Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
Chronic HCV Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 99.0; 100.0; 100.0; 83.3 percentage of participants
Phase 3 N=41 A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Factor XIII Deficiency
Primary: The Incidence of Spontaneous Bleeding Events Requiring Treatment (Treatment is Defined as Administration of a FXIII-Containing Product to Treat the Bleeding Event) — 0…
Phase 2 N=23 Rituximab to Treat Severe Hemophilia A
Hemophilia A
Primary: Proportion of Subjects With Major Response, i.e. Inhibitor Level Falls to Less Than 5 BU/mL Between Weeks 6 to 22 and Remains Below 5 BU/mL at 5-7 Days Following…
Phase 3 N=35 Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency
Congenital Afibrinogenemia · Congenital Hypofibrinogenemia
Primary: Single-dose Pharmacokinetics (PK) of BT524: Terminal Elimination Half-life (t1/2) for Fibrinogen Antigen — 67.9 hours
Phase 2 N=15 A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency
Factor XIII Deficiency
Primary: Peak FXIII Concentration at Steady State — 0.9 Units/mL
Phase 3 N=34 Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors
Hemophilia A With Inhibitors
Primary: Number of Bleeds During 6 Month Treatment Period — 13.1; 5.0 bleeds — p=<0.001
Phase 4 N=21 Prophylaxis Regimen for Hemophilia A Patients
Hemophilia A · Prophylaxis of Bleeding
Primary: Overall Number of Participants With Favorable Outcome on the Score-assigned Prophylaxis Regimen — 12 participants
Phase 4 N=25 Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B
Hemophilia B
Primary: Percentage of Participants Who Developed Factor IX (FIX) Inhibitors — 0 Percentage of participants
Phase 1 N=24 Thrombosomes® in Bleeding Thrombocytopenic Patients
Thrombocytopenia · Hematologic Diseases · Bone Marrow Aplasia
Primary: Number of Patients With Treatment-Emergent Adverse Events (TEAE) — 7; 6; 5 Participants
N/A N=1,439 Epidemiology of Severe Peroperative Bleeding During Scheduled Surgery
Surgery · Blood Loss
Primary: Unanticipated Bleeding — 0; 100; 0 percentage of participants
N/A N=103 An Observational Study to Evaluate Physical Activity, Bleeding Incidence and Health Related Quality of Life, in Participants With Haemophilia A Without Inhibitors Receiving Standard of Care Treatment
Severe Hereditary Factor VIII Deficiency Disease Without Inhibitor · Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor · Haemophilia A
Primary: Mean Number of Daily Active Minutes of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study…
Phase 3 N=9 A Study to Investigate Bio Product Laboratory Ltd (BPL's) Factor X in the Prophylaxis of Bleeding in Children <12 Years
Factor X Deficiency
Primary: The Number of Participants With Excellent Reduction in Bleeding When Given FACTOR X as Routine Prophylaxis Over 6 Months — 9 Participants
Phase 3 N=41 Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
Congenital Bleeding Disorder · Congenital FXIII Deficiency
Primary: Rate (Number Per Subject Year) of Bleeding Episodes Requiring Treatment With a FXIII Containing Product During the Treatment Period — 0.138 bleeding episodes per subject…
Phase 3 N=145 Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura
Acquired Thrombotic Thrombocytopenic Purpura
Primary: Time to Platelet Count Response — 2.69; 2.88 days — p== 0.0099
Phase 3 N=134 A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A
Hemophilia A
Primary: Annualized Number of Total Bleeds in On-demand Treatment Arm (Weeks 0 -36) and in Each Prophylaxis Arm (Weeks 10 - 36, Excluding Rescue Bleeds) - Part A, Main Trial…
N/A N=86 PROPACT: Retrospective Prophylaxis Patient Case Collection
Congenital Bleeding Disorder · Haemophilia A With Inhibitors · Haemophilia B With Inhibitors
Primary: Percent Change in Total Bleed Episodes Per Month - Bleeding Population — -45 percent change (%) in bleeds per month
Phase 3 N=57 Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures
Blood Coagulation Disorders · Hemorrhage
Primary: Change in Hemoglobin Level — -0.6; -0.4 g/dL
Phase 3 N=330 American Trial Using Tranexamic Acid in Thrombocytopenia
Thrombocytopenia
Primary: Bleeding Within 30 Days — 73; 78 Participants
Phase 4 N=1 Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IX
Hemophilia B
Primary: Number of Participants Reporting Efficacy